FAR 27.204-1—Use of patented technology under the United States-Mexico-Canada Agreement.
Plain-English Summary
FAR 27.204-1 is a narrow cross-reference provision that tells contracting officers what to do when a procurement raises questions about the use of patented technology in the context of the United States-Mexico-Canada Agreement (USMCA). The section does not create a detailed patent-licensing rule of its own; instead, it directs the contracting officer to consult legal counsel whenever the USMCA and patented technology issues may affect the acquisition. It also flags Article 20.6(a) of the Agreement, which addresses public health and pharmaceuticals, as a specific point of reference. In practice, this section exists to ensure that patent-related procurement decisions are reviewed for treaty compliance, legal risk, and any special treatment that may apply to health-related or pharmaceutical technologies. For contractors and contracting officers, the practical significance is that patent questions under USMCA should not be handled informally or by assumption; they require legal review before the acquisition proceeds or terms are finalized.
Key Rules
Consult legal counsel
When a question arises about use of patented technology under the USMCA, the contracting officer should seek advice from legal counsel. The rule is precautionary and recognizes that treaty interpretation and patent issues may require specialized legal analysis.
USMCA patent issues are covered
This section applies only when the procurement involves questions about patented technology in the USMCA context. It is not a general patent clause, but a direction for handling treaty-related patent concerns during acquisition planning or contract administration.
Public health note
The section specifically notes Article 20.6(a) of the USMCA, which concerns public health and pharmaceuticals. This signals that procurements involving medical products, pharmaceuticals, or related technologies may require particular attention.
No standalone procurement rule
FAR 27.204-1 does not itself authorize or prohibit use of patented technology. Instead, it functions as a referral provision, meaning the contracting officer must rely on counsel and the applicable treaty language to determine the proper course.
Responsibilities
Contracting Officer
Identify when a procurement raises questions about patented technology under the USMCA and consult legal counsel before taking action. The contracting officer should not resolve treaty or patent interpretation issues independently.
Legal Counsel
Provide legal advice on the applicability of the USMCA to patented technology issues, including any implications of Article 20.6(a) for public health and pharmaceuticals. Counsel should help determine whether the contemplated use is permissible and what contract terms or safeguards may be needed.
Agency
Ensure contracting personnel know to route USMCA patent questions to legal counsel and maintain procedures for legal review of treaty-sensitive acquisitions. The agency should support consistent handling of patent-related issues across procurements.
Contractor
Raise any known patent or licensing issues relevant to performance, especially where the work may involve patented technology or pharmaceutical/public health subject matter. The contractor should provide accurate information needed for legal and acquisition review.
Practical Implications
This section is a trigger for legal review, not a self-contained answer. If a procurement may involve patented technology under USMCA, the contracting officer should pause and get counsel involved early.
The biggest pitfall is assuming ordinary patent rules apply without checking the treaty. USMCA can introduce special considerations, especially for public health and pharmaceuticals.
Contracting officers should document the issue and the legal advice received so the file shows why a particular approach was taken.
Contractors working on health, biotech, or pharmaceutical procurements should expect additional scrutiny and may need to disclose patent or licensing information sooner than in a routine buy.
Because the section is brief, the real substance comes from the treaty text and legal interpretation. Users should treat this FAR provision as a pointer to deeper analysis, not as the final rule.
Official Regulatory Text
When questions arise with regard to use of patented technology under the United States-Mexico-Canada Agreement, the contracting officer should consult with legal counsel. Note that Article 20.6(a) of the Agreement discusses public health and pharmaceuticals.